Are weight-loss drugs like gym memberships? The answer is worth billions
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
This is the best company to work for in the U.S; here are the top 10 that make up the list
A recent award ceremony which is actually significant revealed about the best companies right now existing in the country US ...
Louisville's second annual India Fest draws thousands
General Hospital star Laura Wright is known for being a powerhouse, but only a year ago, the Daytime Emmy-winner and soap ...
Eli Lilly plans to expand its pipeline to address obesity-related conditions in India, says top executive
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...
Ibj.com7d
Proposed federal rule change reflects challenges, opportunities for Indiana’s disabled workers
The state has for several years been moving toward competitive integrated employment, in which people with disabilities work ...
Outsourcing-pharma7d
The largest pharma acquisitions of 2024
From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.
The Financial Express10d
Blockbuster weight loss drug Tirzepatide coming to India soon: Benefits, weight loss potential, and side effects
This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...
The Financial Express12d
Weight loss pills Ozempic, Wegovy and Trizepatide enter Indian market
Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...
Benzinga.com14d
Eli Lilly's Options: A Look at What the Big Money is Thinking
Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...